That’s not correct, the company is seeking approval for their first registered product, no further studies required from The looks of it. The other “food” you refer to is an FDA medicine in late phase. Educate yourself on the market, study phase and market opportunity of FDA vet meds before commenting there because you’re clearly undereducated in that field. The cash burn has reduced significantly and appears to be dropping further. Let’s stick to facts there. And POC studies in humans will be under a $1m but create significant value. If you’re not aware, that’s how biotechs get bigger.. you know, by doing actual work? That’s pretty good progress if you ask me
AC8 Price at posting:
8.5¢ Sentiment: Buy Disclosure: Held
(20min delay)